Comparison of pyrosequencing, sanger sequencing, and melting curve analysis for detection of low-frequency macrolide-resistant Mycoplasma pneumoniae quasispecies in respiratory specimens

Journal of Clinical Microbiology

Volumn 51, Issue 8, 2013, Pages 2592-2598

  Chan, Kwok Hung ^a   To, Kelvin K W ^a,b,c,d   Chan, Betsy W K ^a   Li, Clara P Y ^a   Chiu, Susan S ^d   Yuen, Kwok Yung ^a,b,c,d   Ho, Pak Leung ^a,b,c,d  

^a Department of Microbiology ^*  (Hong Kong)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Research Centre of Infection and Immunology   (Hong Kong)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

MACROLIDE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE MUTATION; GENE TRANSFER; GENETIC PROCEDURES; GENOTYPE; HONG KONG; HUMAN; INTERMETHOD COMPARISON; LIMIT OF DETECTION; MACROLIDE RESISTANT MYCOPLASMA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MELTING CURVE ANALYSIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; QUANTITATIVE ANALYSIS; RESPIRATORY SYSTEM; SANGER SEQUENCING; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DNA, RIBOSOMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; MACROLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; TRANSITION TEMPERATURE; YOUNG ADULT;

EID: 84880589798     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00785-13     Document Type: Article

References (47)

1. Klapdor B, Ewig S, Pletz MW, Rohde G, Schütte H, Schaberg T, Welte T, CAPNETZ Study Group. 2012. Community-acquired pneumonia in younger patients is an entity on its own. Eur. Respir. J. 39:1156-1161.
2. Stuckey-Schrock K, Hayes BL, George CM. 2012. Community-acquired pneumonia in children. Am. Fam. Physician 86:661-667.
3. Johansson N, Kalin M, Tiveljung-Lindell A, Giske CG, Hedlund J. 2010. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin. Infect. Dis. 50:202-209.
4. Duffy LB, Crabb D, Searcey K, Kempf MC. 2000. Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp. J. Antimicrob. Chemother. 45(Suppl 1):29-33.
5. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, Bai L, Zhang JZ, Liu YM, Zhang YY, Wang H, Wang C. 2010. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China. Clin. Infect. Dis. 51: 189-194.
6. Chironna M, Sallustio A, Esposito S, Perulli M, Chinellato I, Di Bari C, Quarto M, Cardinale F. 2011. Emergence of macrolide-resistant strains during an outbreak of Mycoplasma pneumoniae infections in children. J. Antimicrob. Chemother. 66:734-737.
7. Yamada M, Buller R, Bledsoe S, Storch GA. 2012. Rising rates of macrolide-resistant Mycoplasma pneumoniae in the central United States. Pediatr. Infect. Dis. J. 31:409-410.
8. Morozumi M, Takahashi T, Ubukata K. 2010. Macrolide-resistant Mycoplasma pneumoniae: characteristics of isolates and clinical aspects of community-acquired pneumonia. J. Infect. Chemother. 16:78-86.
9. Zhao F, Liu G, Wu J, Cao B, Tao X, He L, Meng F, Zhu L, Lv M, Yin Y, Zhang J. 2013. Surveillance of macrolide-resistant Mycoplasma pneumoniae in Beijing, China, from 2008 to 2012. Antimicrob. Agents Chemother. 57:1521-1523.
10. Principi N, Esposito S. 2013. Macrolide-resistant Mycoplasma pneumoniae: its role in respiratory infection. J. Antimicrob. Chemother. 68: 506-511.
11. Lung DC, Chan YH, Kwong L, Que TL. 2011. Severe communityacquired pneumonia caused by macrolide-resistant Mycoplasma pneumoniae in a 6-year-old boy. Hong Kong Med. J. 17:407-409.
12. Wang Y, Qiu S, Yang G, Song L, Su W, Xu Y, Jia L, Wang L, Hao R, Zhang C, Liu J, Fu X, He J, Zhang J, Li Z, Song H. 2012. An outbreak of Mycoplasma pneumoniae caused by a macrolide-resistant isolate in a nursery school in China. Antimicrob. Agents Chemother. 56:3748-3752.
13. Suzuki Y, Itagaki T, Seto J, Kaneko A, Abiko C, Mizuta K, Matsuzaki Y. 2012. Community outbreak of macrolide-resistant Mycoplasma pneumoniae in Yamagata, Japan in 2009. Pediatr. Infect. Dis. J. 32:237-240.
14. To KKW, Chan KH, Fung YF, Yuen KY, Ho PL. 2010. Azithromycin treatment failure in macrolide-resistant Mycoplasma pneumoniae pneumonia. Eur. Respir. J. 36:969-971.
15. Lucier TS, Heitzman K, Liu SK, Hu PC. 1995. Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 39:2770-2773.
16. Yoo SJ, Kim HB, Choi SH, Lee SO, Kim SH, Hong SB, Sung H, Kim MN. 2012. Differences in the frequency of 23S rRNA gene mutations in Mycoplasma pneumoniae between children and adults with communityacquired pneumonia: clinical impact of mutations conferring macrolide resistance. Antimicrob. Agents Chemother. 56:6393-6396.
17. Spuesens EB, Meijer A, Bierschenk D, Hoogenboezem T, Donker GA, Hartwig NG, Koopmans MP, Vink C, van Rossum AM. 2012. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in the Netherlands. J. Clin. Microbiol. 50:1999-2004.
18. Spuesens EB, Hoogenboezem T, Sluijter M, Hartwig NG, van Rossum AM, Vink C. 2010. Macrolide resistance determination and molecular typing of Mycoplasma pneumoniae by pyrosequencing. J. Microbiol. Methods 82:214-222.
19. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM. 2008. Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob. Agents Chemother. 52:3542-3549.
20. Peuchant O, Ménard A, Renaudin H, Morozumi M, Ubukata K, Bébéar CM, Pereyre S. 2009. Increased macrolide resistance of Mycoplasma pneumoniae in France directly detected in clinical specimens by real-time PCR and melting curve analysis. J. Antimicrob. Chemother. 64:52-58.
21. Li X, Atkinson TP, Hagood J, Makris C, Duffy LB, Waites KB. 2009. Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates. Pediatr. Infect. Dis. J. 28:693-696.
22. Li SL, Sun HM, Zhao HQ, Cao L, Yuan Y, Feng YL, Xue GH. 2012. A single tube modified allele-specific-PCR for rapid detection of erythromycin-resistant Mycoplasma pneumoniae in Beijing. Chin. Med. J. (Engl.) 125:2671-2676.
23. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, Suzuki I, Andoh T, Kenri T, Sasaki Y, Horino A, Shintani M, Arakawa Y, Sasaki T. 2004. Characterization and molecular analysis of macrolideresistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob. Agents Chemother. 48:4624-4630.
24. Lindström A, Odeberg J, Albert J. 2004. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J. Clin. Microbiol. 42:4788-4795.
25. Armenia D, Vandenbroucke I, Fabeni L, Van Marck H, Cento V, D'Arrigo R, Van Wesenbeeck L, Scopelliti F, Micheli V, Bruzzone B, Lo Caputo S, Aerssens J, Rizzardini G, Tozzi V, Narciso P, Antinori A, Stuyver L, Perno CF, Ceccherini-Silberstein F. 2012. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J. Infect. Dis. 205:557-567.
26. Mello FC, Lago BV, Lewis-Ximenez LL, Fernandes CA, Gomes SA. 2012. Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients. BMC Microbiol. 12:96. doi:10.1186/1471-2180-12-96.
27. Newman RM, Kuntzen T, Weiner B, Berical A, Charlebois P, Kuiken C, Murphy DG, Simmonds P, Bennett P, Lennon NJ, Birren BW, Zody MC, Allen TM, Henn MR. 2013. Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants. J. Infect. Dis. 208:17-31.
28. Arvia R, Corcioli F, Simi L, Orlando C, De Santis R, Facchini M, Donatelli I, Azzi A. 2012. Monitoring the susceptibility to oseltamivir of influenza A(H1N1) 2009 virus by nested-PCR and pyrosequencing during the pandemic and in the season 2010-2011. J. Virol. Methods 184:113-116.
29. Averbuch D, Hidalgo-Grass C, Moses AE, Engelhard D, Nir-Paz R. 2011. Macrolide resistance in Mycoplasma pneumoniae, Israel, 2010. Emerg. Infect. Dis. 17:1079-1082.
30. Hung IF, Cheng VC, Wu AK, Tang BS, Chan KH, Chu CM, Wong MM, Hui WT, Poon LL, Tse DM, Chan KS, Woo PC, Lau SK, Peiris JS, Yuen KY. 2004. Viral loads in clinical specimens and SARS manifestations. Emerg. Infect. Dis. 10:1550-1557.
31. To KK, Wong SC, Xu T, Poon RW, Mok KY, Chan JF, Cheng VC, Chan KH, Hung IF, Yuen KY. 2013. Use of nasopharyngeal aspirate for diagnosis of pneumocystis pneumonia. J. Clin. Microbiol. 51:1570-1574.
32. Versalovic J, Funke G, Landry ML, Warnock DW. 2011. Manual of clinical microbiology, 11th ed. ASM Press, Washington, DC.
33. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY. 2013. Hyperimmune intravenous immunoglobulin treatment: a multicentre double-blind randomized controlled trial for patients with severe A(H1N1)pdm09 infection. Chest doi:10.1378/chest.12-2907.
34. Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV. 2012. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States. Antiviral Res. 93:381-386.
35. Chen N, Pinsky BA, Lee BP, Lin M, Schrijver I. 2011. Ultrasensitive detection of drug-resistant pandemic 2009 (H1N1) influenza A virus by rare-variant-sensitive high-resolution melting-curve analysis. J. Clin. Microbiol. 49:2602-2609.
36. Nishijima N, Marusawa H, Ueda Y, Takahashi K, Nasu A, Osaki Y, Kou T, Yazumi S, Fujiwara T, Tsuchiya S, Shimizu K, Uemoto S, Chiba T. 2012. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One 7:e35052. doi:10.1371/journal.pone.0035052.
37. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY, Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C, Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM, Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48:1769-1778.
38. Cardinale F, Chironna M, Dumke R, Binetti A, Daleno C, Sallustio A, Valzano A, Esposito S. 2011. Macrolide-resistant Mycoplasma pneumoniae in paediatric pneumonia. Eur. Respir. J. 37:1522-1524.
39. Itagaki T, Suzuki Y, Seto J, Abiko C, Mizuta K, Matsuzaki Y. 2013. Two cases of macrolide resistance in Mycoplasma pneumoniae acquired during the treatment period. J. Antimicrob. Chemother. 68:724-725.
40. Miyashita N, Kawai Y, Akaike H, Ouchi K, Hayashi T, Kurihara T, Okimoto N, Atypical Pathogen Study Group. 2012. Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect. Dis. 12:126. doi:10.1186/1471-2334-12-126.
41. Miyashita N, Oka M, Atypical Pathogen Study Group, Kawai Y, Yamaguchi T, Ouchi K. 2010. Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia. Int. J. Antimicrob. Agents 36:384-385.
42. Liu Y, Ye X, Zhang H, Xu X, Wang M. 2012. Multiclonal origin of macrolide-resistant Mycoplasma pneumoniae isolates as determined by multilocus variable-number tandem-repeat analysis. J. Clin. Microbiol. 50:2793-2795.
43. Benitez AJ, Diaz MH, Wolff BJ, Pimentel G, Njenga MK, Estevez A, Winchell JM. 2012. Multilocus variable-number tandem-repeat analysis of Mycoplasma pneumoniae clinical isolates from 1962 to the present: a retrospective study. J. Clin. Microbiol. 50:3620-3626.
44. Pereyre S, Charron A, Hidalgo-Grass C, Touati A, Moses AE, Nir-Paz R, Bébéar C. 2012. The spread of Mycoplasma pneumoniae is polyclonal in both an endemic setting in France and in an epidemic setting in Israel. PLoS One 7:e38585. doi:10.1371/journal.pone.0038585.
45. Pereyre S, Touati A, Petitjean-Lecherbonnier J, Charron A, Vabret A, Bébéar C. 2013. The increased incidence of Mycoplasma pneumoniae in France in 2011 was polyclonal, mainly involving M. pneumoniae type 1 strains. Clin. Microbiol. Infect. 19:E212-E217. doi:10.1111/1469-0691.12107.
46. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M. 2010. Characterization of macrolide resistance in Mycoplasma pneumoniae isolated from children in Shanghai, China. Diagn. Microbiol. Infect. Dis. 67:355-358.
47. Liu Y, Ye X, Zhang H, Xu X, Li W, Zhu D, Wang M. 2009. Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China. Antimicrob. Agents Chemother. 53:2160-2162. China